

The logo for the University of Maryland (UMD) is displayed in yellow text on a red rectangular background.

FUNDING ALERT

Notes

1. Weekly opt-in funding alert provided by the UMD-College Park Division of Research and [SSTI](#). Please feel free to forward this alert to colleagues.
2. If you have been forwarded this email and would like to receive this alert on a weekly basis, please fill out the following form: <http://go.umd.edu/fundingalert>.

SSTI (July 19)

New Federal R&D Funding Opportunities

Department of Defense

Smart Non-invasive Assays of Physiology

The DARPA Biological Technologies Office invites proposals to develop a portable, multi-omic, multiplexed sensor prototype capable of implementing models that assess warfighter physiological states based on molecular biomarkers. The ideal final prototype is intended to be a salivary assay, smaller than a typical cell phone, which objectively measures warfighter readiness for militarily relevant tasks in less than 30 minutes. Other biofluids will be considered, though a strong case must be presented to support biofluids other than saliva. Proposed research must include the development of innovative approaches that enable revolutionary advances in portable biochemical sensing. Specifically excluded is research that primarily results in incremental improvements to the existing state of practice frames.

Awards:

Multiple awards are anticipated.

Eligibility:

Unrestricted.

Deadline:

08/11/2022

AwardsID(s):

HR001122S0044

Links:

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=342113>

Traumatic Brain Injury and Psychological Health

The Army invites proposals for five funding opportunities through the Traumatic Brain Injury and Psychological Health research program. Responses to any of the five must address at least one of the subtopics listed within three focus areas described in each announcement. The deadline for proposals in response to the first three opportunities listed below is September 14:

- The **Translational Research Award** supports projects that will accelerate the movement of promising ideas in psychological health conditions and/or TBI research into clinical applications, including healthcare products, technologies, and/or clinical practice guidelines. Proposals may include preclinical and/or clinical research involving human subjects and human anatomical substances. The FY22 TBIPHRP opportunity may also support ancillary studies that are associated with an ongoing or completed clinical trial and projects that optimize the design of future clinical trials. Responses must address one of the subtopics listed within three focus areas described in the announcement. Up to 10 TRA awards may be made from an estimated pool of \$15.5 million. For W81XWH-22-TBIPHRP-TRA, please refer to the link below ending with oppld=342447
- The **Patient-Centered Research Award** supports projects that bridge the gap between research, practice, and policy by building a knowledge base on how interventions, clinical practices/guidelines, tools, and policies can be deployed to targeted populations at the appropriate time at the point of need. Funding from this award mechanism must support clinical research or clinical trials but cannot be used for preclinical or animal research. A pool of \$23.25 million is anticipated to support up to 15 awards. For W81XWH-22-TBIPHRP-PCRA, please refer to the link below ending with oppld=342449.
- **Investigator Initiated Research Awards** support studies that will make an important contribution toward understanding, preventing, assessing, and treating psychological health conditions and/or traumatic brain injury. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. The Army anticipates making 17 awards from a total pool of \$13.17 million. For W81XWH-22-TBIPHRP-IIRA, please refer to the link below ending with oppld=342450.

The deadline for both of the following two opportunities is December 8.

- Up to 26 **Clinical Trial Awards** may be made from a pool of \$70.52 million to support the rapid implementation of clinical trials with the potential to have a significant impact on psychological health conditions and/or TBI through clinical applications, including healthcare products, technologies, and/or practice guidelines. Proposed

projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations. Proposals/applications proposing comparative effectiveness, implementation science, healthcare services research as the primary research objective should consider the FY22 TBIPHRP Patient-Centered Research Award (described briefly above). For W81XWH-22-S-TBIPH1, please refer to the link below ending with oppld=342451.

- The **Focused Program Award** supports research and accelerate solutions to a critical question or overarching challenge related to at least one sub-area within one of the three FY22 TBIPHRP FPA Focus Areas described in the announcement. Four awards may be made from a total pool of \$31 million. Proposals/applications shall include multiple, distinct research projects led by individual project leaders that address complementary aspects of the overarching challenge. Collaborations between researchers at military or Veterans institutions and non-military institutions are strongly encouraged. For W81XWH-22-S-TBIPH2, please refer to the link below ending with oppld=342467.

Awards:

Multiple awards of varying length and sizes (see individual announcements).

Eligibility:

Unrestricted (foreign and domestic entities are eligible.)

AwardsID(s):

W81XWH-22-TBIPHRP-TRA, W81XWH-22-TBIPHRP-PCRA, W81XWH-22-TBIPHRP-IIRA, W81XWH-22-S-TBIPH1, W81XWH-22-S-TBIPH2

Links:

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=342447>, <https://www.grants.gov/web/grants/view-opportunity.html?oppld=342449>, <https://www.grants.gov/web/grants/view-opportunity.html?oppld=342450>, <https://www.grants.gov/web/grants/view-opportunity.html?oppld=342451>, <https://www.grants.gov/web/grants/view-opportunity.html?oppld=342467>

Department of Energy

Centers of Excellence for research in the Stewardship Science Academic Alliances

Defense Programs Office of Strategic Partnership Programs announces their interest in receiving applications for new or renewal cooperative agreement financial assistance awards for Centers of Excellence for research in the Stewardship Science Academic Alliances (SSAA) Program. Only applications for cooperative agreements awards will be accepted for this solicitation, no grant applications will be considered.

The specific areas of interest are:

1. Advanced Characterization of Materials Properties under Extreme Conditions
2. Low Energy Nuclear Science
3. Radiochemistry
4. High Energy Density Physics

The SSAA Program was established in 2002 provides the research experience necessary to maintain a cadre of trained scientists at U.S. universities to meet the nation's current and future Stockpile Stewardship Program needs, with a focus on those areas not supported by other federal agencies.

Awards:

Multiple five-year awards ranging from \$5 million to \$12.5 million.

Eligibility:

U.S. institutions of higher education

Deadline:

08/22/2022

AwardsID(s):

DE-FOA-0002789

Links:

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=342003>

Photovoltaics R&D

The Office of Energy Efficiency and Renewable Energy invites research proposals in photovoltaic (PV) modules to reduce costs and supply chain vulnerabilities; achieve durable, recyclable solar technologies; and advance perovskite photovoltaic technologies. Projects may last from 24 to 60 months. A 20% cost share of total project costs is required for all R&D awards; 50% for all demonstration projects. Mandatory letters of intent are due August 3.

Awards:

Twelve awards from a total pool of \$29 million.

Eligibility:

Unrestricted domestically (with the exception of federal labs and FFRDCs).

Deadline:

08/03/2022

AwardsID(s):

DE-FOA-0002582

Links:

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=342293>

Solar Manufacturing "Incubator"

The Office of Energy Efficiency & Renewable Energy invites applications from small and large for-profit businesses to support projects that enable continued cost reductions, while developing next-generation solar technologies and boosting American solar manufacturing,

especially in cadmium telluride (CdTe) photovoltaics. Applicants are particularly encouraged to partner with a diverse set of organizations to advance demonstration and field testing activities. This program addresses key barriers to bringing commercial solutions closer to the market that are too risky for the private sector to support on its own. Lowering these barriers will allow solar companies to attract private investment and commercialize solutions. Two topic areas are identified in the announcement:

1. R&D activities with the goal of develop new products or manufacturing processes across the solar value chain. (A 20% cost-share is required)
2. Demonstration activities related to CdTe technology. (50% cost share required)

Letters of intent are required.

Awards:

Up to 24 awards maybe made, ranging individually from \$500,000 to \$10 million.

Eligibility:

Only for-profit entities and teams led by for-profit entities are eligible. Foreign businesses are eligible to be prime recipients.

Deadline:

09/16/2022

AwardsID(s):

DE-FOA-0002609

Links:

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=342404>

Department of Health and Human Services

BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development

The National Institute of Biomedical Imaging and Bioengineering solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. The feasibility should be established by the end of its first phase and serve as a foundation for the transition to its second phase. Fully developing the technology into a functional prototype and validating it by in-vivo animal or human function/connectivity imaging are anticipated in the second phase. The research plan should provide a realistic timeline and tangible milestones to support the proposed development effort.

Awards:

Application budgets are limited to \$300,000 in direct costs excluding consortium F&A in any year for the UG3 phase. Applications should rarely exceed \$750,000 in direct costs excluding consortium F&A in any year for the UH3 phase.

Eligibility:

Unrestricted (foreign and domestic entities are eligible)

Deadline:

10/13/2022

AwardsID(s):

RFA-EB-22-001

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-22-001.html>

Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies

The National Institute of Diabetes and Digestive and Kidney Diseases seeks to accelerate the pace of scientific research towards prevention of type 1 diabetes. To this end, NIDDK is committed to providing opportunities to maximize the use of existing samples and data to increase our understanding of type 1 diabetes etiology and pathogenesis in humans. This opportunity is intended to fund collaborative projects using samples from participants in type 1 diabetes clinical studies or trials. Such participants have been well-characterized for risk of developing type 1 diabetes (for example, phenotypically and genetically), and in many cases followed for many years before and after the development of clinical symptoms. In addition, samples from clinical trials provide the opportunity to test additional effects of interventions on mechanisms of progression to clinical symptoms.

Awards:

NIDDK intends to commit \$5 million in Fiscal Year 2023 to fund 3-4 awards

Eligibility:

Unrestricted (foreign and domestic entities are eligible)

Deadline:

01/28/2023

AwardsID(s):

RFA-DK-22-021

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-021.html>

Epigenetic Mechanisms Regulating HIV CNS Latency and Neuropathogenesis Using Novel Single Cell Technologies

The National Institute on Mental Health is looking to support studies on the epigenetic mechanisms regulating HIV Central Nervous System (CNS) latency and/or neuropathogenesis using in-vitro (macrophages, microglia and astrocytes, organoids), ex-vivo (post-mortem tissues) and in-vivo systems (animal models). Strategies to target epigenetic pathways for achieving sustained HIV remission and treatment of HIV associated-CNS dysfunction are encouraged. The use of novel single cell technologies is also strongly encouraged but is not a requirement. Basic and translational research in domestic and international settings are of

interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data may be most appropriate for announcement RFA-MH-22-281, while applicants with preliminary data may wish to apply using the R01 mechanism (RFA.-22-280)

Awards:

\$2,000,000 in FY 2023 to fund 3-5 awards in response to this FOA and the companion RFA-MH-22-281

Eligibility:

Unrestricted (foreign and domestic entities are eligible)

Deadline:

11/05/2022

AwardsID(s):

RFA-MH-22-280, RFA-MH-22-281

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-280.html>, <https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-281.html>

Galvanizing Health Equity Through Novel and Diverse Educational Resources

The Office of Research on Women's Health invites proposals for educational activities that complement and/or enhance the training of a workforce to meet the nation's diverse biomedical, behavioral and clinical research needs. Activities can integrate knowledge of sex and gender influences into existing trainings or develop novel methods or curricula. Supported curricula will be made freely available, at no cost to the broader community, through the ORWH website; programs must be self-sustaining at the end of the award period. Applicants are expected to define and describe the goals and objectives of the proposed curriculum or methods development program, including a rationale for the activities and a clear description of how the activities will advance the field.

Deadline:

09/27/2022

AwardsID(s):

RFA-OD-22-015

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-015.html>

Human Islet Research Network - Consortium on Targeting and Regeneration

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication or islet cell plasticity, reprogramming of non-beta cells into beta-like cells, or shielding of residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research

Network (HIRN). The long-term outcome of the projects proposed in response to the current initiative should be the development of safe and highly-specific products or reagents that could be administered orally or systemically to patients with T1D, at risk of developing T1D and could have a reasonable chance of being used in the clinic in the foreseeable future.

Awards:

\$3.75 million for FY 2023 to fund 4-6 awards. Application budgets are limited to \$600,000 direct costs per year

Eligibility:

Unrestricted Domestically

Deadline:

09/26/2022

AwardsID(s):

RFA-DK-22-009

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-009.html>

Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes

The National Institute of Diabetes and Digestive and Kidney Diseases encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community [e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)]. The proposed assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum.

Awards:

Up to \$1.0 million to fund one award in Fiscal Year 2023.

Eligibility:

Unrestricted Domestically

Deadline:

09/26/2022

AwardsID(s):

RFA-DK-21-031

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-031.html>

Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations

The National Institute of General Medical Sciences invites qualified academic or research institutions to apply for funding support to purchase advanced equipment that will enhance and modernize research-supporting operations of biomedical research facilities. Targeted are laboratory research core facilities, animal research facilities, and other similar shared-use research spaces. The goal is to strengthen research-auxiliary activities of biomedical research facilities and to enhance the efficiency of their operations. NIGMS will consider co-funding applications from higher education institutions that award undergraduate (B.S. or B.A.) and/or graduate degrees in biomedical sciences and have received no more than \$6 million dollars per year (total costs) from NIH Research Project Grants (RPGs) in each of the preceding two fiscal years, calculated using NIH RePORTER, at the time of the application.

Awards:

The maximum award budget is \$350,000, direct costs only. Applications with a budget less than \$50,000 will not be considered. For requests of multiple pieces of the same equipment, the minimum budget for each piece is \$15,000.

Eligibility:

Unrestricted Domestically

Deadline:

11/07/2022

AwardsID(s):

PAR-22-190

Links:

<https://grants.nih.gov/grants/guide/pa-files/PAR-22-190.html>

Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy

The National Institute on Drug Abuse seeks to support clinical trials that will evaluate multi-level interventions for patients who are using long-term opioid therapy to manage chronic pain for whom risks of continuing opioid therapy may outweigh the benefits of continued opioid use. NIDA seeks studies for pharmacologic management with or without non-pharmacological approaches for managing chronic pain in those currently using long-term opioids. Interventions can target patients, health care providers (inclusive of pharmacists) or health care systems to reduce chronic pain and opioid-related risks and improve quality of life.

Awards:

A pool of \$6.75 million in FY 2023 to fund 6-7 awards.

Eligibility:

Unrestricted Domestically

Deadline:

08/27/2022

AwardsID(s):

RFA-DA-23-041, RFA-DA-23-042

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-041.html>, <https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-042.html>

NCI Clinical and Translational Exploratory/Developmental Studies

The National Cancer Institute supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, comparative oncology, symptom management, or reduction of cancer disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant *in vivo* or *in vitro* tumor models; and strategies to address therapeutic outcome disparities among underserved populations.

Awards:

Up to \$275,000 over two years

Eligibility:

Unrestricted (foreign and domestic entities are eligible)

Deadline:

10/10/2022

AwardsID(s):

PAR-22-216

Links:

<https://grants.nih.gov/grants/guide/pa-files/PAR-22-216.html>

Point-of-Care Technologies Research Network: Technology Research and Development Centers

The purpose of this funding opportunity announcement is to solicit Technology Research and Development Center (TRDC) applications for the Point-of-Care Technologies Research Network (POCTRN). The POCTRN catalyzes innovation in diagnostic technologies through a network model that enhances complementary strengths and builds multidisciplinary partnerships across scientific/technological, clinical, regulatory, and commercialization domains. Each TRDC will accelerate the development, validation, and deployment of point-of-care, home-based and other innovative testing technologies in a specific area of health research.

Awards:

Application budgets are not limited but it is strongly recommended that applicants not request a budget of more than \$1.2M in direct costs per year

Eligibility:

Unrestricted Domestically

Deadline:

08/26/2022

AwardsID(s):

PAR-22-203

Links:<https://grants.nih.gov/grants/guide/pa-files/PAR-22-203.html>**Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain**

The National Center for Complementary and Integrative Health invites applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. The overall goal of this initiative is to support the "real world" assessment of pain management interventions and/or health care strategies to enhance adherence to pain management guidelines in health care systems that may lead to improved SCD pain management, allowing access to opioid pain management when needed. Two awards are offered, based on whether or not the proposal includes a clinical trial.

- The **Clinical Trials Required** Award (RFA-AT-23-002) seeks to support clinical trials that will evaluate multi-level interventions for patients who are using long-term opioid therapy to manage chronic pain for whom risks of continuing opioid therapy may outweigh the benefits of continued opioid use. NIDA seeks studies for pharmacologic management with or without non-pharmacological approaches for managing chronic pain in those currently using long-term opioids. Interventions can target patients, health care providers (inclusive of pharmacists) or health care systems to reduce chronic pain and opioid-related risks and improve quality of life.
- The **Clinical Trials Optional** Award (RFA-AT-23-001) seeks applications for a single resource center to complement a broader HEAL program on reducing opioid-related harms and improving quality of life in patients on long-term opioid therapy (LTOT). Key responsibilities include: (1) Provide logistical and coordination support for this broader research program; (2) Create a risk-benefit decision tool to assist providers in determining when opioids should be continued as prescribed, tapered, or tapered and discontinued; (3) Create a clinical definition, identifying associated symptoms/behaviors, and generating a screening tool for individuals on LTOT for whom harms outweigh the benefits; (4) Validate the clinical definition, associated behaviors and symptoms, and screening tool in an independent sample. Applicants are expected to form a community steering committee consisting of multiple stakeholders, including patients with lived experience, to guide these efforts.

Awards:

Budgets for RFA-AT-23-001 are limited to \$500,000/year in direct costs; for RFA-AT-23-002, budgets are limited \$1 million/year in direct costs.

Eligibility:

Unrestricted Domestically

Deadline:

10/21/2022

AwardsID(s):

RFA-AT-23-001, RFA-AT-23-002

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-23-001.html>, <https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-23-002.html>

Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants

The National Institute on Drug Abuse requests applications for studies designed to develop and test sustainable, scalable interventions to prevent opioid misuse, opioid use disorder, and co-occurring mental health conditions by intervening directly on social determinants of health. This initiative aims to build an evidence base for preventive interventions that address inequities, social risks and/or social disadvantage. Interventions targeting social determinants may be structural (e.g. policy, regulatory, or systemic-wide changes) or designed to alter outcomes of individuals affected by contextual risk factors, and may be implemented in conjunction with psychosocial interventions designed to address behavioral risks.

Awards:

\$10,000,000 in FY 2023 to fund up to 15 awards

Eligibility:

Unrestricted Domestically

Deadline:

01/02/2023

AwardsID(s):

RFA-DA-23-051

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-051.html>

Single-Site Investigator-Initiated Clinical Trials

The National Heart, Lung, and Blood Institute supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should

address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives.

Awards:

Application budgets are not limited but need to reflect the actual needs of the proposed project

Eligibility:

Unrestricted (foreign and domestic entities are eligible)

Deadline:

09/11/2022

AwardsID(s):

PAR-22-189

Links:

<https://grants.nih.gov/grants/guide/pa-files/PAR-22-189.html>

Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19

The National Institute of Diabetes and Digestive and Kidney Diseases invites applications to support a team of multiple investigators for a study to establish a longitudinal cohort of individuals who developed diabetes following SARS-CoV-2 infection to understand the pathophysiology and clinical course post-COVID-19 diabetes. The cohort must include children and adults and reflect the geography and demographics of COVID-19 in the U.S. There must be an appropriate comparator population recruited and followed. The goals are to determine the contribution of: 1) specific pathophysiologic pathways; 2) overall health impact of the pandemic; 3) COVID-19 severity, and 4) COVID-19 treatment upon excess new onset diabetes from SARS-CoV-2 infection and response to diabetes therapy.

Awards:

One multi-year award with an annual direct cost budget not to exceed \$3.65 million.

Eligibility:

Unrestricted Domestically

Deadline:

11/20/2022

AwardsID(s):

RFA-DK-22-016

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-016.html>

Department of Homeland Security

HBCU National Nuclear Forensics Expertise Development Program

The DHS Countering Weapons of Mass Destruction Office invites proposals from Historically Black Colleges and Universities for its Nuclear Forensics Research Award. NFRA supports the linkage of a two qualified graduate students with a nuclear forensics- relevant research project, that will serve as the basis of their Ph.D.-level theses and be completed through work at a partner laboratory and the student's home university. Through faculty and laboratory staff participation, a collaborative research process is established through which each selected graduate fellow is jointly mentored, further enhancing his or her understanding of the nuclear forensics field. The award includes full tuition and a stipend for 36-60 months. Four technical mission area priorities, described in the announcement, must be taken into consideration when developing the research project:

1. Pre-Detonation Material and Device Signatures
2. Pre-Detonation Analysis Methods and Tools
3. Post-Detonation Material Collection and Analysis Methods
4. Post-Detonation Prompt Signal Analysis

Awards:

1-2 awards, each no more than \$465,000 per year.

Eligibility:

Restricted to HBCUs

Deadline:

08/30/2022

AwardsID(s):

DHS-22-DN-130-NFRA-HBCU

Links:

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=342468>

New SBIR/STTR Funding Opportunities

Department of Health and Human Services

Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases

The National Center for Advancing Translational Sciences invites SBIR Fast Track proposals to support basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease, and in the process to identify and overcome challenges in adapting the oncology basket trial model to rare diseases. Projects proposed for this announcement will require individuals with expertise in carrying out clinical trials in rare diseases. Applicants are strongly encouraged to collaborate with investigators at academic institutions and negotiate an agreement for carrying out the proposed clinical trials. NCATS will give priority to projects involving clinical investigators who are part of the Rare Disease Clinical Research Network (RDCRN) and which focus on diseases under study in the RDCRN.

Awards:

Budgets up to \$325,000 total costs per year for Phase I and up to \$2M total costs per year for Phase II may be requested when applying under the waiver topic.

Eligibility:

U.S. small business concerns

Deadline:

11/18/2022

AwardsID(s):

RFA-TR-22-029

Links:

<https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-029.html>

[Terms and Conditions for redistribution or republication of the *SSTI Funding Supplement*](#)

Preparation of the *SSTI Funding Supplement* is possible only through the financial support of dues-paying SSTI member organizations. Use of the *SSTI Funding Supplement* is subject to the following terms and conditions:

- Only the primary member contact, or their SSTI-approved designee, may redistribute this newsletter and/or its content and under no circumstances may the *SSTI Funding Supplement* be placed on a website or database accessible to the general public.
- Any redistribution must be limited to the SSTI member organization's staff, faculty, membership, partner organizations, and client companies.
- All redistributions must include fundingsupplement@ssti.org in the distribution list, give credit to SSTI (including a link to <https://ssti.org>), and include this Terms and Conditions statement.
- Those receiving a redistributed version of the *SSTI Funding Supplement* may not forward those emails to others or make them available to the public.
- With prior permission from SSTI, only the primary member contact, or their SSTI-approved designee, may post back issues of the *SSTI Funding Supplement* on internal and password-protected sites only.

If you have any questions about these terms, to request approval of a primary contact's designee, or to discuss an alternative licensing agreement, please contact Colin Edwards at fundingsupplement@ssti.org.